On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease
- PMID: 12643297
- DOI: 10.1016/s1590-8658(02)80259-6
On-demand proton pump inhibitor therapy in patients with gastro-oesophageal reflux disease
Abstract
On-demand therapy is an established modality in long-term therapy with histamine-2-receptor antagonists, in cases of mild non-erosive gastro-oesophageal reflux disease. In the literature, only a few studies have specifically addressed the problem of proton pump inhibitors on-demand treatment. The evidence, so far, available suggests that this might be an effective modality of long-term treatment in the majority of patients with non-erosive gastro-oesophageal reflux disease. This treatment modality appears to be the most cost-effective and the best tolerated medical regimen for gastro-oesophageal reflux disease. It also seems to be able to restore the impairment of health-related quality of life due to gastro-oesophageal reflux disease symptoms. Although the current standard of care for patients with non-erosive gastro-oesophageal reflux disease is maintenance therapy with daily administration of a proton pump inhibitor agent, on-demand therapy, with the same drug, may be a reasonable long-term choice. The ideal proton pump inhibitors for such treatment will be those with a more rapid onset of action, more profound acid inhibition, more predictable therapeutic effect and less drug-drug interactions. Newer proton pump inhibitors, like esomeprazole, the S-chiral isomer of omeprazole, are promising drugs for on-demand treatment of gastro-oesophageal reflux disease.
Similar articles
-
Medical treatment of gastro-oesophageal reflux disease.Acta Otorhinolaryngol Ital. 2006 Oct;26(5):276-80. Acta Otorhinolaryngol Ital. 2006. PMID: 17345932 Free PMC article. Review.
-
Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients.Aliment Pharmacol Ther. 2005 Jun 1;21(11):1299-312. doi: 10.1111/j.1365-2036.2005.02490.x. Aliment Pharmacol Ther. 2005. PMID: 15932360
-
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.Clin Pharmacokinet. 1996 Nov;31(5):386-406. doi: 10.2165/00003088-199631050-00005. Clin Pharmacokinet. 1996. PMID: 9118586 Review.
-
Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis.Aliment Pharmacol Ther. 2003 Mar 15;17(6):785-92. doi: 10.1046/j.1365-2036.2003.01526.x. Aliment Pharmacol Ther. 2003. PMID: 12641500
-
Esomeprazole: a review of its use in the management of acid-related disorders.Drugs. 2002;62(10):1503-38. doi: 10.2165/00003495-200262100-00006. Drugs. 2002. PMID: 12093317 Review.
Cited by
-
Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.Drugs. 2004;64(4):347-61. doi: 10.2165/00003495-200464040-00001. Drugs. 2004. PMID: 14969571 Review.
-
A review of rabeprazole in the treatment of acid-related diseases.Ther Clin Risk Manag. 2007 Jun;3(3):363-79. Ther Clin Risk Manag. 2007. PMID: 18488081 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical